TY - JOUR AB - The current study presents the case of a 59‑year‑old male with advanced‑stage renal cell carcinoma and bone metastases in the proximal femur and ilium (cT3aN3M1; stage IV). Resection of the primary renal cell cancer and palliative surgery with a γ‑nail for an impending fracture of the right proximal femur were performed, followed by radiotherapy. Sorafenib, a multi‑kinase inhibitor that blocks the raf and tyrosine kinases of the vascular endothelial and platelet‑derived growth factor receptors, was administered for 9 months, resulting in a marked improvement in the metastatic ilium and a reduction in the extent of the lung metastases. The patient suffered minor adverse effects, including a skin rash and mild diarrhea, but remained alive at the time of follow‑up at 36 months post‑surgery. Sorafenib demonstrated efficacy against the bone metastasis of metastatic renal cell carcinoma. AD - Department of Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan AU - Hoshi,Manabu AU - Oebisu,Naoto AU - Takada,Jun AU - Iwai,Tdashi AU - Nakamura,Hiroaki DA - 2015/03/01 DO - 10.3892/ol.2015.2844 EP - 1411 IS - 3 JO - Oncol Lett KW - renal cell cancer sorafenib bone metastasis lung metastasis PY - 2015 SN - 1792-1074 1792-1082 SP - 1409 ST - Case report demonstrating effectiveness of sorafenib in multiple lung and bone metastases of renal cell carcinoma T2 - Oncology Letters TI - Case report demonstrating effectiveness of sorafenib in multiple lung and bone metastases of renal cell carcinoma UR - https://doi.org/10.3892/ol.2015.2844 VL - 9 ER -